Badanie fazy 1b oceniające terapię tarlatamabem w skojarzeniu z ZL-1310 z zastosowaniem lub bez inhibitora PD-L1 u uczestników z drobnokomórkowym rakiem płuca (SCLC).

Kryteria włączenia kto może wziąć udział (8)

1. Age ≥ 18 years (or ≥ legal age within the country if it is older than 18 years) at the time of signing the informed consent.
2. Participants with Histologically or cytologically confirmed SCLC:
3. For Part 1, participants must have SCLC that has progressed or recurred following at least 1 line of platinum-based anti-cancer therapy.
4. For Parts 1 and 2, participants must have progressed or recurred following at least 1 line of platinum-based therapy. No prior tarlatamab is allowed in Cohort 2-1.
5. For Part 3, participants must have extensive-stage SCLC (ES-SCLC) with no prior systemic treatment other than 1 cycle of platinum-based chemotherapy. Note: Participants with prior treatment for limited-stage SCLC (LS-SCLC) before diagnosis of ES SCLC are permitted.
6. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
7. At least 1 measurable lesion as defined per RECIST v1.1 within 21-day screening period, not previously irradiated.
8. Adequate organ function (hematological, coagulation, renal, hepatic, pulmonary, and cardiac function).